Emergent Biosolutions Inc. (NYSE:EBS) Given Consensus Rating of “Hold” by Analysts

Emergent Biosolutions Inc. (NYSE:EBS) has been given an average rating of “Hold” by the five ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $12.00.

A number of brokerages recently weighed in on EBS. UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Finally, Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd.

Emergent Biosolutions Stock Performance

Emergent Biosolutions stock opened at $7.32 on Wednesday. Emergent Biosolutions has a fifty-two week low of $5.61 and a fifty-two week high of $14.06. The firm’s fifty day moving average price is $8.13 and its 200-day moving average price is $9.05. The stock has a market cap of $377.63 million, a P/E ratio of -26.14 and a beta of 2.34. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.46. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.The business had revenue of $156.10 million for the quarter, compared to the consensus estimate of $145.00 million.

Insider Buying and Selling

In other Emergent Biosolutions news, Director Donald W. Degolyer sold 15,481 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $8.40, for a total value of $130,040.40. Following the completion of the sale, the director owned 129,721 shares in the company, valued at approximately $1,089,656.40. The trade was a 10.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paul Anthony Williams sold 3,000 shares of Emergent Biosolutions stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the transaction, the senior vice president directly owned 159,098 shares in the company, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,925 shares of company stock worth $543,512 in the last 90 days. 6.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Emergent Biosolutions

A number of hedge funds have recently modified their holdings of EBS. Pacer Advisors Inc. bought a new position in shares of Emergent Biosolutions during the first quarter valued at about $3,454,000. Bank of America Corp DE raised its position in Emergent Biosolutions by 24.8% during the 1st quarter. Bank of America Corp DE now owns 183,443 shares of the biopharmaceutical company’s stock valued at $1,523,000 after purchasing an additional 36,499 shares during the last quarter. Quantinno Capital Management LP bought a new position in Emergent Biosolutions during the 1st quarter valued at approximately $127,000. Renaissance Technologies LLC grew its position in shares of Emergent Biosolutions by 13.7% in the 1st quarter. Renaissance Technologies LLC now owns 656,047 shares of the biopharmaceutical company’s stock worth $5,445,000 after buying an additional 78,900 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in shares of Emergent Biosolutions in the 1st quarter worth approximately $159,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.